UK markets close in 3 hours 14 minutes
  • FTSE 100

    7,020.14
    +36.64 (+0.52%)
     
  • FTSE 250

    22,538.42
    +66.38 (+0.30%)
     
  • AIM

    1,251.03
    +2.90 (+0.23%)
     
  • GBP/EUR

    1.1521
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3810
    +0.0026 (+0.19%)
     
  • BTC-GBP

    44,068.55
    -1,223.35 (-2.70%)
     
  • CMC Crypto 200

    1,354.15
    -26.80 (-1.94%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CRUDE OIL

    63.59
    +0.13 (+0.20%)
     
  • GOLD FUTURES

    1,779.50
    +12.70 (+0.72%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,415.91
    +160.58 (+1.05%)
     
  • CAC 40

    6,260.16
    +26.02 (+0.42%)
     

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Sanofi
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARIS, France – March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-and-csr-reports.

In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the “Document d’Enregistrement Universel” is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.



About Sanofi



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



Sanofi, Empowering Life



Media Relations Contact
Ashleigh Koss
Tel: +1 (908) 981-8745
Ashleigh.Koss@sanofi.com



Sandrine Guendoul
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com






Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine
Yvonne Naughton



Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco



IR main line:
Tel.: +33 (0)1 53 77 45 45
investor.relations@sanofi.com



https://www.sanofi.com/en/investors/contact



Attachment